{
    "clinical_study": {
        "@rank": "116140", 
        "acronym": "menocor", 
        "arm_group": {
            "arm_group_label": "diagnostic", 
            "description": "quality of life score and dosage"
        }, 
        "brief_summary": {
            "textblock": "Prospective multicenter study, Out Health Products that evaluates to 2 years the impact of\n      chemo-induced menopause (MCI) on the functional score of quality of life questionnaire\n      QLQ-C30 in young women age childbearing and living with breast cancer."
        }, 
        "brief_title": "Study the Impact of Chemo-induced Menopause on the Quality of Life in Young Women of Childbearing Age and Diagnosed With Non-metastatic Breast Cancer", 
        "condition": "BREAST CANCER", 
        "condition_browse": {
            "mesh_term": "Breast Neoplasms"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patient aged over 18 and under 45\n\n          -  Patient without amenorrhea at diagnosis\n\n          -  Performance status 2 (according to WHO criteria )\n\n          -  Patient diagnosed with histologically proven breast cancer , non metastatic Clinical\n             Stages I , IIA , IIB and IIIA\n\n          -  Positive Hormone Receptors (defined by a rate of 10% of labeled cells and\n             immunohistochemistry (IHC) ) or negative\n\n          -  Status HER2 positive or HER2 negative ( defined a score of 0 or 1 + by IHC , or a 2 +\n             score by IHC and FISH / ISHS / CISH negative)\n\n          -  Patients treated with neoadjuvant or adjuvant chemotherapy hematological, renal and\n             hepatic functions satisfying : ANC> 2,109 / L, platelets > 100 . 109 / L, Hb> 10 g /\n             dl , normal bilirubin, AST and ALT <2.5 upper normal value ( VNS) , alkaline\n             phosphatase <2.5 VSN , creatinine clearance > 60 ml / min\n\n          -  Obtaining informed consent in writing, signed and dated\n\n          -  Affiliation Social Security system (or be the beneficiary of such a plan ) under the\n             terms of the Act of August 9, 2004\n\n        Exclusion Criteria:\n\n          -  Patient male\n\n          -  Cancer metastatic\n\n          -  Any tumor T4 ( skin invasion , deep grip, inflammatory breast cancer )\n\n          -  Patient who underwent surgical castration of ovariectomy type hysterectomy or tubal\n             ligation\n\n          -  Please have endometriosis\n\n          -  Please pregnant or nursing\n\n          -  Please not using effective contraception\n\n          -  Patient who have had hormone therapy or chemotherapy\n\n          -  Patient who have already taken similar Gn -RH or LH -RH (chemical castration)\n\n          -  Patient whose mother was early menopause without treatment\n\n          -  Presence of comorbidities related to fertility or medical history related to\n             fertility ovarian failure types or sterility\n\n          -  significant neurological or psychiatric abnormalities\n\n          -  Inability of the patient to complete the questionnaires ( the language barrier )\n\n          -  Private Patient freedom by court or administrative\n\n          -  Patient with another pathology deemed incompatible with the input of the patient in\n             the protocol\n\n          -  Participation in another clinical trial involving the chemical or surgical castration\n             of the patient\n\n          -  Please geographically unstable in the next 6 months or residing away from the\n             treatment center and thereby making it difficult to monitor"
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "45 Years", 
            "minimum_age": "18 Years", 
            "sampling_method": "Probability Sample", 
            "study_pop": {
                "textblock": "premenopausal women with age between 18 to 45 years. premenopausal women with breast\n        cancer non metastatic."
            }
        }, 
        "enrollment": {
            "#text": "240", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 20, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02102568", 
            "org_study_id": "2013-A01284-41"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "May 5, 2014", 
        "location": [
            {
                "contact": {
                    "last_name": "Joyce DOHOU", 
                    "phone": "0033463663337"
                }, 
                "facility": {
                    "address": {
                        "city": "Clermont-ferrand", 
                        "country": "France", 
                        "zip": "63000"
                    }, 
                    "name": "Centre Jean PERRIN"
                }, 
                "investigator": {
                    "last_name": "Marie-Ange MOURET-REYNIER", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Joyce DOHOU", 
                    "phone": "0033463663337"
                }, 
                "facility": {
                    "address": {
                        "city": "Le puy-en Velay", 
                        "country": "France"
                    }, 
                    "name": "Centre Emile Roux"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "last_name": "JOYCE DOHOU", 
                    "phone": "0033463663337"
                }, 
                "facility": {
                    "address": {
                        "city": "Reims", 
                        "country": "France"
                    }, 
                    "name": "Institut Jean Godinot"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Joyce DOHOU", 
                    "phone": "0033463663337"
                }, 
                "facility": {
                    "address": {
                        "city": "Saint Etienne", 
                        "country": "France"
                    }, 
                    "name": "Institut Lucien Neuwirth"
                }, 
                "status": "Not yet recruiting"
            }
        ], 
        "location_countries": {
            "country": "France"
        }, 
        "number_of_groups": "1", 
        "overall_contact": {
            "email": "joyce.dohou@cjp.fr", 
            "last_name": "Joyce DOHOU", 
            "phone": "0033463663337"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "France: ANSM-Agence Nationale de Securite du medicament", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "April 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Evaluation of the 2-year impact of chemo-induced menopause (MCI) on the functional score of quality of life questionnaire QLQ-C30 in young women of childbearing age and diagnosed with breast cancer.", 
            "safety_issue": "No", 
            "time_frame": "until 12 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02102568"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Evaluation of the rate of MCI after chemotherapy", 
                "safety_issue": "No", 
                "time_frame": "until 6 months"
            }, 
            {
                "measure": "Sensitivity and Specificity of Anti-Mullerian Hormone blood AMH in the prediction of MCI", 
                "safety_issue": "No", 
                "time_frame": "until 6 months"
            }, 
            {
                "measure": "Predictive value of amenorrhea 6 months to 2 years of menopause", 
                "safety_issue": "No", 
                "time_frame": "until 6 months"
            }, 
            {
                "measure": "Assessment of change in FSH (Follicle Stimulating Hormone) and estradiol before chemotherapy and at the end of chemotherapy", 
                "safety_issue": "No", 
                "time_frame": "until 24 months"
            }, 
            {
                "measure": "Impact of MCI on specific aspects of quality of life (anxiety, depression, body image, sporting activity and quality of sleep) after breast cancer", 
                "safety_issue": "No", 
                "time_frame": "until 24 months"
            }
        ], 
        "source": "Centre Jean Perrin", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Centre Jean Perrin", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "April 2014", 
        "study_design": "Observational Model: Cohort, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "March 2014"
    }
}